Third Circuit Rules in Mylan's Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylan's Breach of

   Third Circuit Rules in Mylan's Favor Regarding Paroxetine Hydrochloride
Extended-Release Tablets, Sending Mylan's Breach of Contract Claim Against GSK
                                   to Trial

PR Newswire

PITTSBURGH, July 23, 2013

PITTSBURGH, July 23, 2013 /PRNewswire/ --Mylan Inc. (NASDAQ: MYL) today
announced that the Third Circuit Court of Appeals has reversed a summary
judgment ruling dismissing Mylan's claim for breach of contract against
GlaxoSmithKline relating to Paroxetine Hydrochloride Extended-release (ER)
Tablets. The court ordered that Mylan's contract claim proceed to trial in
U.S. District Court for the District of New Jersey. Mylan had filed suit
against GSK claiming that GSK's agreement to supply Apotex with Paroxetine
Hydrochloride ER violated Mylan's settlement and license agreement with GSK.
Mylan is seeking money damages and an order permanently enjoining GSK from
supplying Apotex with Paroxetine Hydrochloride ER. The company is pleased with
the court's decision and the case will proceed to trial.

This press release includes statements that constitute "forward-looking
statements," including with regard to litigation and sales of the product.
These statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Because such statements
inherently involve risks and uncertainties, actual future results may differ
materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are
not limited to: strategies by competitors or other third parties to delay or
prevent product introductions; risks inherent in legal and regulatory
processes; and the other risks detailed in the company's periodic filings with
the Securities and Exchange Commission. The company undertakes no obligation
to update these statements for revisions or changes after the date of this

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin, Media, 724.514.1968; or Kris King, Investors,
Press spacebar to pause and continue. Press esc to stop.